Chisato Ohe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chisato Ohe has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Go Kimura
Department of Urology Nippon Medical School Hospital Tokyo Japan
1 shared publication Hidefumi Kinoshita
Kansai Medical University
1 shared publication- Hidefumi Kinoshita
Department of Urology and Andrology Kansai Medical University Hirakata Japan
1 shared publication Hirotsugu Uemura
Department of Urology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan
1 shared publicationJunichi Ikeda
Kansai Medical University
1 shared publication- Kazutoshi Yamana
Department of Urology and Molecular Oncology, Niigata University Graduate school of medical and dental sciences, 1-757 Asahimachi-Dori, Chuo-Ku, Niigata 951-8510, Japan
1 shared publication
Latest Publications
- Open Access
- 23 July 2024
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 12 (7) , e009358-14
Impact of LAG-3/FGL1 pathway on immune evasive contexture and clinical outcomes in advanced urothelial carcinoma
Background: Anti-programmed death-1 (PD-1)/anti-PD-ligand-1 (PD-L1) pathway inhibition is a standard regimen for advanced urothelial carcinoma (UC); however, its limited efficacy has been reflected in reported medium response rates. This study explored the role of next-generation coinhibitory receptors (IRs; lymphocyte activation gene 3 (LAG-3), T-cell immunoglobulin and mucin domain 3 (TIM-3), and T-cell immunoreceptor with Ig and ITIM domains (TIGIT)) and their ligands (LGs) in the response to PD-(L)1 blockade therapy and the oncological outcomes in patients with UC. Methods: We investigated metastatic UC cases who underwent PD-(L)1 therapy (cohort 1: n=348, cohort 2: n=89, and cohort 4: n=29) or advanced UC cases involving surgery (cohort 3: n=293 and cohort 5: n=90). We assessed the mRNA expression profiles and corresponding clinical information regarding IRs and LGs using cohorts 1, 2, and 3. Additionally, we elucidated the spatial features of these targeted markers using multiplex immunohistochemistry (mIHC) on formalin-fixed paraffin-embedded samples from cohorts 4 and 5. Survival, differential expressed gene, and Gene Set Enrichment analyses were performed. For mIHC, quantitative analyses were also performed to correlate immune and tumor cell densities with patient survival. Results: LAG-3 expression was strongly associated with the responsiveness of PD-(L)1 blockade compared with the expression of TIM-3 and TIGIT. In tumors with high LAG-3 levels, the increased expression of fibrinogen-like protein 1 (FGL1) had a significantly negative effect on the response to PD-(L)1 blockade and overall survival. Moreover, high FGL1 levels were associated with elevated CD4+ regulatory T-cell gene signatures and the upregulation of CD39 and neuropilin-1, with both indicating CD8+ T-cell exhaustion. mIHC analyses revealed that patients with stromal CD8+LAG-3+cellshigh–tumor FGL1+cellshigh exhibited a significant negative correlation with survival rates compared with those with stromal CD8+LAG-3+cellshigh–tumor FGL1+cellslow. Conclusions: LAG-3 expression and high FGL1 coexpression are important predictive factors of adverse oncological outcomes related to the presence of immunosuppressive contextures. These findings are hypothesis-generating, warranting further mechanistic and clinical studies aimed to evaluate LAG-3/FGL1 blockade in UC.
- 23 July 2024
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 12 (7) , e009358-14
Open AccessImpact of LAG-3/FGL1 pathway on immune evasive contexture and clinical outcomes in advanced urothelial carcinoma
Background: Anti-programmed death-1 (PD-1)/anti-PD-ligand-1 (PD-L1) pathway inhibition is a standard regimen for advanced urothelial carcinoma (UC); however, its limited efficacy has been reflected in reported medium response rates. This study explored the role of next-generation coinhibitory receptors (IRs; lymphocyte activation gene 3 (LAG-3), T-cell immunoglobulin and mucin domain 3 (TIM-3), and T-cell immunoreceptor with Ig and ITIM domains (TIGIT)) and their ligands (LGs) in the response to PD-(L)1 blockade therapy and the oncological outcomes in patients with UC. Methods: We investigated metastatic UC cases who underwent PD-(L)1 therapy (cohort 1: n=348, cohort 2: n=89, and cohort 4: n=29) or advanced UC cases involving surgery (cohort 3: n=293 and cohort 5: n=90). We assessed the mRNA expression profiles and corresponding clinical information regarding IRs and LGs using cohorts 1, 2, and 3. Additionally, we elucidated the spatial features of these targeted markers using multiplex immunohistochemistry (mIHC) on formalin-fixed paraffin-embedded samples from cohorts 4 and 5. Survival, differential expressed gene, and Gene Set Enrichment analyses were performed. For mIHC, quantitative analyses were also performed to correlate immune and tumor cell densities with patient survival. Results: LAG-3 expression was strongly associated with the responsiveness of PD-(L)1 blockade compared with the expression of TIM-3 and TIGIT. In tumors with high LAG-3 levels, the increased expression of fibrinogen-like protein 1 (FGL1) had a significantly negative effect on the response to PD-(L)1 blockade and overall survival. Moreover, high FGL1 levels were associated with elevated CD4+ regulatory T-cell gene signatures and the upregulation of CD39 and neuropilin-1, with both indicating CD8+ T-cell exhaustion. mIHC analyses revealed that patients with stromal CD8+LAG-3+cellshigh–tumor FGL1+cellshigh exhibited a significant negative correlation with survival rates compared with those with stromal CD8+LAG-3+cellshigh–tumor FGL1+cellslow. Conclusions: LAG-3 expression and high FGL1 coexpression are important predictive factors of adverse oncological outcomes related to the presence of immunosuppressive contextures. These findings are hypothesis-generating, warranting further mechanistic and clinical studies aimed to evaluate LAG-3/FGL1 blockade in UC.
- Open Access
- 25 July 2022
- Published by Springer Nature in Research Square
Deep learning-based predictions of clear and eosinophilic phenotypes in clear cell renal cell carcinoma
We have recently shown that histological phenotypes focusing on clear and eosinophilic cytoplasm in clear cell renal cell carcinoma (ccRCC) correlated with prognosis and the response to angiogenesis inhibition and checkpoint blockade. This present study aims to develop an artificial intelligence (AI) model for predicting clear or eosinophilic phenotypes in ccRCC using the TCGA-KIRC dataset and to demonstrate if the predicted phenotypes correlate with pathological factors and gene signatures related to angiogenesis and cancer immunity. Prior to the development of the AI model, histological evaluation using hematoxylin and eosin (H&E) whole-slide images of the TCGA-KIRC cohort (n = 435) was performed by a urologic pathologist, similar to our previous studies, and successfully shown that clear and eosinophilic histological phenotypes correlated with clinicopathological characteristics, gene signatures, and prognosis, confirming that our diagnostic method based on the histological phenotypes by using the TCGA-KIRC cohort consisting of multi-institutional slides was valid. The AI model was developed as follows. First, the highest-grade area on each whole slide image was captured for image processing. Second, the selected regions were cropped into tiles to develop the AI model. Third, the AI was trained using transfer learning on a deep convolutional neural network, and clear or eosinophilic predictions were scaled as AI scores. Next, we verified the AI model using a validation cohort (n = 95). Finally, we evaluated the accuracy of the prognostic predictions of the AI model and revealed that the AI model detected clear and eosinophilic (mixed or predominantly eosinophilic) phenotypes with high prediction. The AI model stratified the patients’ outcomes in the TCGA-KIRC cohort (p = 0.008) and predicted eosinophilic phenotypes correlated with adverse clinicopathological characteristics and high immune-related gene signatures. In conclusion, an AI-based histologic subclassification accurately predicts clear or eosinophilic phenotypes in ccRCC allowing for consistently reproducible stratification for prognostic and therapeutic stratification.
- 25 July 2022
- Published by Springer Nature in Research Square
Open AccessDeep learning-based predictions of clear and eosinophilic phenotypes in clear cell renal cell carcinoma
We have recently shown that histological phenotypes focusing on clear and eosinophilic cytoplasm in clear cell renal cell carcinoma (ccRCC) correlated with prognosis and the response to angiogenesis inhibition and checkpoint blockade. This present study aims to develop an artificial intelligence (AI) model for predicting clear or eosinophilic phenotypes in ccRCC using the TCGA-KIRC dataset and to demonstrate if the predicted phenotypes correlate with pathological factors and gene signatures related to angiogenesis and cancer immunity. Prior to the development of the AI model, histological evaluation using hematoxylin and eosin (H&E) whole-slide images of the TCGA-KIRC cohort (n = 435) was performed by a urologic pathologist, similar to our previous studies, and successfully shown that clear and eosinophilic histological phenotypes correlated with clinicopathological characteristics, gene signatures, and prognosis, confirming that our diagnostic method based on the histological phenotypes by using the TCGA-KIRC cohort consisting of multi-institutional slides was valid. The AI model was developed as follows. First, the highest-grade area on each whole slide image was captured for image processing. Second, the selected regions were cropped into tiles to develop the AI model. Third, the AI was trained using transfer learning on a deep convolutional neural network, and clear or eosinophilic predictions were scaled as AI scores. Next, we verified the AI model using a validation cohort (n = 95). Finally, we evaluated the accuracy of the prognostic predictions of the AI model and revealed that the AI model detected clear and eosinophilic (mixed or predominantly eosinophilic) phenotypes with high prediction. The AI model stratified the patients’ outcomes in the TCGA-KIRC cohort (p = 0.008) and predicted eosinophilic phenotypes correlated with adverse clinicopathological characteristics and high immune-related gene signatures. In conclusion, an AI-based histologic subclassification accurately predicts clear or eosinophilic phenotypes in ccRCC allowing for consistently reproducible stratification for prognostic and therapeutic stratification.